Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shanghai Hep Pharmaceutical Co. Ltd. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. Sergio Coffa is identified as the busiest examiner, responsible for 1 pending office action.
This structure shows that the company's prosecution involves multiple administrative units and different examiners for its pending biotechnology applications. The presence of 2 pending office actions indicates an active and distributed patent portfolio across the patent office's pharmaceutical divisions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.5% |
| AUDET, MAURY A | 1 | 50.1% | +23.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16759200 | Drug and Method for Treating Liver Diseases Related to Hepatitis B Viruses in Full-Dose Condition | COFFA, SERGIO | 86d overdue |
| 16757067 | Therapeutic Drug for Non-Alcoholic Fatty Liver Disease | AUDET, MAURY A | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16759200 | Drug and Method for Treating Liver Diseases Related to Hepatitis B Viruses in Full-Dose Condition | COFFA, SERGIO | 1658 | §103DP | Non-Final OA | 86d overdue | Pending | Apr 24, 2020 |
| 16757067 | Therapeutic Drug for Non-Alcoholic Fatty Liver Disease | AUDET, MAURY A | 1654 | §103 | Non-Final OA | — | Pending | Apr 17, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial